Evaluation of Sloan-Charts for Assessment of Disease Progress in Multiple Sclerosis
NCT ID: NCT01272596
Last Updated: 2021-07-29
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
100 participants
OBSERVATIONAL
2009-12-31
2013-11-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
The primary aim of this study is to investigate, whether in MS patients contrast acuity and sensitivity change over a period of two years.
Secondary aims are the correlation of visual contrast parameters with structural retinal changes and quality of life.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
CHRONIC OPTIC NEUROPATHY IN MULTIPLE SCLEROSIS
NCT02543788
Multimodal Exploration of Patients With Multiple Sclerosis for an Early Detection of Subtle Progression
NCT05941975
Assessment of NfL and GFAP Levels, Atrophy of the Macula GCC by OCT and Whole Brain Atrophy by MRI to Predict Evolution of Neurological Disability in MS Patients
NCT04860947
Analysis of Neurodegenerative Process Within Visual Ways In Multiple Sclerosis
NCT03656055
Use of a Smartphone Application to Predict the Prognosis in Patients With Newly Diagnosed Multiple Sclerosis.
NCT04595799
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Multiple Sclerosis Patients
Patients with Clinically Isolated Syndrome or definite Multiple Sclerosis (either relapsing-remitting or secondary progressive)
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Written Informed Consent
Exclusion Criteria
* Significant Cognitive Impairment
* Severely Decreased Visual Acuity
* Preexisting Severe Retinal Pathology
18 Years
65 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Novartis Germany GmbH
UNKNOWN
Charite University, Berlin, Germany
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Jan-Markus Dörr
PI
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Jan M Dörr, MD
Role: PRINCIPAL_INVESTIGATOR
NeuroCure Clinical Research Center, Charité Universitaetsmedizin Berlin
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
NeuroCure Clinical Reserach Center, Charité Universitaetsmedizin
Berlin, , Germany
Countries
Review the countries where the study has at least one active or historical site.
Related Links
Access external resources that provide additional context or updates about the study.
NeuroCure Clinical Research Center, Charité Berlin, Germany
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
Sloan-Study
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.